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Abstract: Several studies have shown site-specific differences in colorectal cancer (CRC) with respect
to the risk factors. CRC was shown to be associated with cardiovascular risk (CVR) factors, but
site-specific variations have not been investigated so far. This study aimed to assess the associations
between the prevalence and subsite-specific differences of colorectal neoplasia and established CVR
scores or known coronary artery disease (CAD) in a large asymptomatic European screening cohort
(N = 2098). Participants underwent simultaneous screening colonoscopy and CVR evaluation, using
the Framingham Risk Score and Heart Score. Lesions found in the colonoscopy were classified by
location (proximal/distal colon or rectum). More neoplasias were found in the proximal versus the
distal colon (p < 0.001). The Framingham Risk Score and Heart Score showed incremental risk for
colorectal adenoma, across the tertiles in the proximal and the distal colon (p < 0.001). The prevalence
of adenomas in the rectum was much lower, but also here, incremental risk could be shown for the
Framingham Risk but not the Heart Risk Score tertiles. Prevalence of adenomas in the proximal
colon was higher in subjects with type 2 diabetes (T2DM) (p = 0.006), but no association was found
between adenomas and T2DM in the distal colon (p = 0.618) and the rectum (p = 0.071). Males had a
higher CVR and more findings, in the screening colonoscopy, as compared to females, however, no
site-specific differences were noted. Patients with known CAD and high CVR have an increased risk
of colorectal neoplasia in both the proximal and distal colon. Patients with T2DM have a higher risk
for neoplasia in the proximal colon.
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1. Introduction
Colorectal cancer is one of the most common cancers worldwide. In industrialized countries, it is
the third most common cancer in men, after those of the lung and the prostate, and the second most
common in women, after breast cancer [1].
Several differences between the proximal colon (i.e., from the caecum to the transverse colon), the
distal colon (i.e., from the distal colon flexure to the rectum), and the rectum can be found; including
their embryological origin, histological features, physiological function, fecal composition, intestinal
transit time and even the mechanisms of oncogenesis [2–5]. In 1990, Bufill was the first to propose the
concept that cancers originating from the proximal and the distal colon may be viewed as two distinct
forms of cancer, with rectal cancer being a third cancer subtype, all of which are usually summarized
as colorectal cancer (CRC) [2,6]. More recent studies demonstrating the clinical, histopathological, and
molecular differences have supported this theory [7].
Furthermore, several studies have been conducted to assess the subsite-specific risk factor
profiles for cancers in different anatomical locations of the colon and the rectum, with inconclusive
results [8–14].
Emerging evidence suggests an association between coronary artery disease (CAD) and CRC,
possibly due to the shared risk factors, such as obesity, sedentary lifestyle, diabetes mellitus,
hypertension, and cigarette smoking [15–21]. In a recently published study we showed that colorectal
cancer was associated with cardiovascular risk factors in a large Caucasian cohort [22]. To the best of
our knowledge, we are not aware of studies investigating if the associations between cardiovascular
risk factors differ between the different sites of colorectal neoplasias, in screening colonoscopy. Thus,
the aim of this study was to assess the site-specific differences of colorectal neoplasia in patients with
differing cardiovascular risk profiles.
2. Methods
2.1. Subjects
The study was conducted using participants of a health screening program (Salzburg Colon
Cancer Prevention Initiative, SAKKOPI) at the Department of Internal Medicine, Oberndorf Hospital,
between 2010 and 2014. All patients without gastrointestinal symptoms that wished to be screened
according to the national screening recommendations and agreed to participate in the study, were
included [23,24]. This study complies with the Declaration of Helsinki and was approved by the
local ethics committee (Ethikkommision des Landes Salzburg, approval no. 415-E/1262/2-2010).
Informed consent was obtained from all participants.
2.2. Clinical Assessment
In this single-centre study, study participants were examined on two consecutive days. On the
first day, the participants filled out a standardized questionnaire, underwent a physical examination,
and venous blood was collected, after an overnight fast. On the second day, a screening colonoscopy
was performed.
In total, two thousand one hundred and thirty-eight Caucasian subjects, without gastrointestinal
symptoms, were screened. One hundred and twelve subjects presenting with gastrointestinal
symptoms were excluded from the study.
Blood pressure was measured twice after a 5 min rest in a sitting position and the average was
taken, arterial hypertension was defined as ≥140/90 mmHg. Waist circumference was measured at
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the highest point of the iliac crest, with subjects standing in an upright position. Metabolic syndrome
was evaluated as defined by the National Cholesterol Education Program Adult Treatment Panel [25].
Body mass index was calculated as weight divided by squared body height (kg/m2).
2.3. Questionnaire
A detailed medical history, including the participant’s current medication, was obtained. Smoking
status was classified as “never smokers”, “former smokers”, and “current smokers”. A reported history
of coronary artery disease was verified by a review of the medical records and it was checked whether
the diagnosis had been established by coronary angiography.
2.4. Laboratory Assessment
Cholesterol, triglycerides, HDL (high density lipoprotein) cholesterol, insulin, glucose, and HbA1c
(glycated hemoglobin A1c) were measured in the fasting venous blood probe. A standardized oral
glucose tolerance test was performed with 75 g of glucose in 300 mL of water. Type 2 diabetes was
classified as the use of diabetes medication, HbA1c ≥ 6.5%, oral glucose tolerance test > 11.1 mmol/L,
after 2 h, or fasting glucose >7.0 mmol/L, respectively. Impaired fasting glucose (IFG) was defined as
fasting glucose <7.0 but >6.1 mmol/L, impaired glucose tolerance (IGT) was defined as oral glucose
tolerance test <11.1 but >7.8 mmol/L, after 2 h [26]. Homeostatic Model Assessment for Insulin
Resistance (HOMA-IR) was calculated, as previously suggested, to estimate the insulin resistance:
HOMA-IR = (Fasting insulin [mg/dL]) ∗ (Fasting glucose [mg/dL])/405 [27].
2.5. Cardiovascular Risk Assessment
Two widely used cardiovascular risk scores were calculated for every subject—the Framingham
Risk Score (FRS) and the Heart Score (HS), for low-risk countries (as Austria is a low-risk country) of
the European Society of Cardiology (ESC) [28,29]. Forty subjects aged >79 years had to be excluded
from the study, as the FRS was not validated in these patients. HS was originally designed for subjects
aged 40–65 years, however, the formula allows to calculate the HS for subjects >65 years with the
caveat that the cardiovascular risk will most likely be underestimated in these subjects. Both FRS and
HS are not validated in diabetic patients. We did, however, include diabetic subjects in our analysis and
performed a separate analysis, excluding all diabetic subjects. As the results of including or excluding
diabetics were essentially the same, we report the results including the diabetic subjects to allow for
greater generalizability of our results.
2.6. Colonoscopy
The laxative Polyethylene Glycol and Electrolytes (Klean-Prep®) was used for bowel preparation.
After analysis of the macroscopic and the histologic results, the colonoscopic findings were classified as
tubular adenoma, advanced neoplasia, i.e., adenoma with villous or tubulovillous features, size ≥1 cm
or high-grade dysplasia, or carcinoma [30,31]. Lesions were classified by location—the proximal colon
(including caecum), the ascending and transverse colon, the distal colon ranging from the splenic
flexure to the sigmoid, and the rectum [32].
2.7. Statistics
We used Statistica 7.0 (Statsoft) and Stata 13.0 (Stata Corporation, College Station, TX, USA)
statistical software for the calculations. For comparison of the categorical variables, we used a
contingency χ2 test and the non-parametric nptrend test, across the ordered groups. We estimated
the odds ratios (ORs), with 95% confidence intervals (CI), by univariate logistic regression analysis.
To provide separate ORs for the middle and the upper FRS and the HS tertiles, we used two “dummy”
variables with the respective low-tertile as a reference. Similar analyses were used to estimate the ORs
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for low, intermediate, and high CVR groups, stratified according to the various FRS and HS levels that
have been previously used by others [33,34].
To translate the results into a clinically-relevant effect size, we report the number needed to
be screened (NNS), i.e., the total number of subjects screened divided by the number of subjects
with a pathological finding in the screening colonoscopy. The calculation of the AUC (area under
the curve) was realized with R’s “pROC“ package (receiver-operating-characteristic), based on the
continuous measures of the FRS and HS. Sensitivity (true positives/(true positives + false negatives))
and specificity ((true negatives/(true negatives + false positives)) for being in the high cardiovascular
risk tertile was likewise calculated. Correlation matrix with Spearman’s rho was calculated to test for
correlation of pre-diabetic states with the findings of the screening colonoscopy.
3. Results
3.1. Differences by Coronary Risk Profiles
Two thousand and ninety-eight subjects were included in the final analysis, including one hundred
and eight subjects (5%) with a self-reported history of CAD, which was verified using the health records.
The proportion of men, the mean values for age, BMI (body mass index), and FRS and HS scores, were
significantly higher in subjects with a history of CAD, in comparison to the subjects without CAD
history. Moreover, type 2 diabetes mellitus and metabolic syndrome were significantly more common
in the group with a CAD history, while the prevalence of hypertension, measured blood pressure, and
smoking history were comparable in the two groups (see Table 1). Except for Aspirin use, the clinical
characteristics (shown in Table 1) did not differ significantly between the angiographically-verified
CAD group and the group without angiography but with a positive CAD history (Supplementary
Table S1).
Table 1. Characteristics of subjects with and without CAD History.
Variable No CAD History CAD History p
N 1990 108
Age (years, [mean ± SD]) 58.7 ± 9.7 66.6 ± 7.5 <0.001
Males (n, [%]) 982 (49.4) 69 (63.9) 0.003
BMI (kg/m2) 27.1 ± 4.8 28.2 ± 4.5 0.026
Systolic blood pressure (mmHg) 133.7 ± 19.2 131.7 ± 18.6 0.280
Diastolic blood pressure (mmHg) 79.6 ± 9.0 80.9 ± 11.1 0.229
Smoking status
(never/ever/current, n, [%])
968 (48.6)/703 (35.4)/319
(16.0)
49 (45.4)/46 (42.6)/13
(12) 0.250
Hypertension (n, [%]) 1242 (62.4) 70 (64.8) 0.615
IFG (n, [%]) 143 (7.3) 24 22.2 <0.001
IGT (n, [%]) 330 (16.5) 21 (19.4) 0.437
HOMA-IR 2.8 ± 6.1 4.6 ± 6.5 0.003
HbA1c [%] 5.8 ± 0.7 6.1 ± 0.7 <0.001
Diabetes (n, [%]) 262 (13.2) 35 (32.4) <0.001
Metabolic Syndrome (n, [%]) 385 (19.4) 39 (36.1) <0.001
FRS 7.1 ± 6.0 11.5 ± 6.8 <0.001
HS 3.0 ± 3.6 4.8 ± 3.6 <0.001
Aspirin (n, [%]) 264 (13.2) 83 (76.9) <0.001
Subjects with and without CAD (Coronary artery disease) history differed significantly, with respect to age,
gender, BMI (body mass index), presence of type 2 diabetes impaired fasting glucose (IFG), Homeostatic Model
Assessment for Insulin Resistance (HOMA-IR), glycated hemoglobin A1c (HbA1c), presence of metabolic syndrome,
Framingham Risk Score (FRS), Heart Score (HS) of the European Society of Cardiology, and Aspirin use, but did not
differ in smoking status, blood pressure (mmHg, millimeter of mercury), impaired glucose tolerance (IGT), and
presence of arterial hypertension.
Subjects without a history of CAD were divided into the approximate tertiles, according to their
FRS and HS. The FRS upper limits of 3% and 8%, for the low- and intermediate-risk groups, were used.
Thus, seven hundred and eleven subjects were assigned to the low, six hundred and thirty-three to the
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intermediate, and six hundred and forty-six to the high tertiles. The same tertile sizes were used for
the HS, to facilitate comparison.
3.2. Cardiovascular Risk Profile and Site-Specific Colonoscopic Results
Subjects with known CAD history and high cardiovascular risk profiles had a higher probability
of colorectal neoplasia, as reported previously, see Figure 1, Tables 2–4 [22].
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Figure 1. Odds ratios for any adenoma and advanced neoplasia. The odds ratios (ORs) for the
prevalence of any adenoma, more than doubled in the Framingham Risk Score (FRS) and the Heart
Score (HS) of the European Society of Cardiology intermediate tertiles, and tripled in the upper FRS
and HS tertiles, relative to the respective low tertiles (a,b). ORs for having advanced neoplasia only
marginally increased in the intermediate tertiles, but showed a more than three-fold increase in the
upper tertiles of the FRS and the HS (c,d).
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Table 2. Colorectal lesion and advanced neoplasia by CAD history.
CAD
History Total N
Subjects
with Any
Adenoma
N (%)
N to be
Screened
OR
(95% CI) p-Value
Subjects
with
Advanced
Neoplasia
N to be
Screened
OR
(95% CI) p-Value
No 1990 526 (26.4) 3.8 Reference 75 (3.8) 26.5 Reference
Yes 108 38 (35.2) 2.8 1.51(1.10–2.27) 0.047 10 (9.6) 10.8
2.62
(1.31–5.20) 0.007
Subjects with CAD (coronary artery disease) history had a higher detection-rate of any adenoma and of advanced
neoplasia, as compared to the subjects without a CAD history.
Table 3. Risk of any adenoma and advanced neoplasia, by one percentage point increases in the risk
scores, in subjects without known CAD.
Risk Score Any Adenoma p-Value Advanced Neoplasia p-Value
FRS (% points) 1.07 (1.06–1.09) <0.001 1.07 (1.04–1.12) <0.001
HS (% points) 1.09 (1.07–1.14) <0.001 1.09 (1.05–1.14 <0.001
The risk of any adenoma and advanced neoplasia increased significantly by one percentage point rise in the
Framingham Risk Score (FRS) and the Heart Score (HS) of the European Society of Cardiology.
For the site-specific analysis, as the number of advanced neoplasia in our population was small,
we were only able to determine associations with the presence of any adenoma. Generally, the
proportion of lesions was greater in the proximal than the distal colon (p < 0.001), and lowest in the
rectum. For both the proximal and the distal colon, the number of lesions gradually increased from
the lowest to the highest tertile of the FRS and HS, with the ORs ranging from 1.7 to 3.0 (p < 0.001,
with the first tertile as the baseline) (Figure 2a–d). For the rectal lesions, similar associations were
observed for the FRS, however, for the HS, the proportions of the rectal lesions were comparable in the
second and the third tertile. In summary, the FRS and the HS showed an incremental risk for colorectal
adenoma across the tertiles, with the exception of HS, with regard to the rectal adenomas (Figure 2,
Tables 5 and 6). The sensitivity and specificity calculations of the site-specific adenoma showed that
high cardiovascular risk, as estimated by the FRS or the HS, is not sensitive (48–51%), but is specific
(68–71%, depending on location) for colorectal adenoma. Likewise, the ROC analysis revealed that
values ranged from 60–65% for the FRS (proximal colon: 64%; distal colon 65%; rectum 62%) and the
HS (proximal colon: 64%; distal colon 64%; rectum: 60%).
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Table 4. Risk of any adenoma or advanced neoplasia by the FRS and the HS risk tertiles.
Any
Adenoma
Advanced
Neoplasia
N N (%) N to beScreened OR (95% CI) Sensitivity Specificity p N (%)
N to be
Screened OR (95% CI) p Sensitivity Specificity
FRS 1990 526 (26.4) 3.8 75 (3.8) 26.5
Low (0–3) 711 111 (15.6) 6.4 Reference 13 (1.8) 54.7 Reference
Intermediate (4–8) 633 168 (26.5) 3.8 1.95(1.49–2.55) <0.001 19 (3.0) 33.3
1.66
(0.81–3.39) 0.163
High (>8) 646 247 (38.2) 2.6 3.35(2.59–4.33) 47% 73% <0.001 43 (6.7) 15.0
3.83
(2.04–7.19) <0.001 57% 69%
HS 1990 526 (26.4) 3.8 75 (3.8) 26.5
Low (<1.077) 711 109 (15.3) 6.5 Reference 12 (1.7) 59.2 Reference
Intermediate
(1.077–3.192) 633 176 (27.8) 3.6
2.13
(1.63–2.78) <0.001 23 (3.6) 27.5
2.20
(1.08–4.45) 0.029
High (3.192) 646 241 (37.3) 2.7 3.29(2.54–4.26) 46% 72% <0.001 40 (6.2) 16.2
3.84
(2.00–7.40) <0.001 53% 68%
Framingham Risk Score (FRS) and Heart Score (HS) of the European Society of Cardiology tertiles showed significant associations with any adenoma and advanced neoplasia. ORs (95%
CI) for FRS high vs. intermediate (reference), for any adenoma—1.71 (1.35–2.17) (p = 0.000). ORs (95% CI), for FRS high vs. intermediate (reference) for advanced neoplasia—2.30 (1.33–4.00)
(p = 0.003). ORs (95% CI) for HS high vs. intermediate (reference), for any adenoma—1.55 (1.22–1.96) (p = 0.000). ORs (95% CI) for HS high vs. intermediate (reference), for advanced
neoplasia—1.75 (1.04–2.96) (0.037).
J. Clin. Med. 2018, 7, 484 8 of 20
J. Clin. Med. 2018, 7, x FOR PEER REVIEW  9 of 20 
 
 
Figure 2. Site-specific odds ratios for any adenoma and advanced neoplasia. Odds Ratios (ORs) for 
having lesions in the proximal or distal colon increased in the intermediate and the upper 
Framingham Risk Score (FRS) and the Heart Score (HS) of the European Society of Cardiology tertiles, 
respectively (a–d). The prevalence of adenomas in the rectum was much lower than in the colon. The 
difference in the distribution of the rectal lesions, according to the cardiovascular risk, was more 
pronounced in the FRS (p < 0.001) than in the HS tertiles (p = 0.039) (e,f). 
  
Figure 2. Site-specific odds ratios for any adeno a and advanced neoplasia. Odds Ratios (ORs) for
having lesions in the proximal or distal colon increased in the intermediate and the upper Framingham
Risk Score (FRS) and the Heart Score (HS) of the European Society of Cardiology tertiles, respectively
(a–d). The prev lence of ad nomas in the rectum was much lo er than in the colon. T differenc in
the distribution of the rectal lesi ns, according t the cardiovascular risk, was more p onounced in the
FRS (p < 0.001) than in the HS tertiles (p = 0.039) (e,f).
J. Clin. Med. 2018, 7, 484 9 of 20
Table 5. Associations of the Framingham Risk (FRS) Tertiles with colorectal lesion, by location.
FRS-Tertiles N N (%) with AnyAdenoma
N to be
Screened OR (95% CI) p-Value Sensitivity Specificity
Proximal
Colon 1990 325 (16.3) 6.1
Low 711 69 (9.7) 10.3
Intermediate 633 100 (15.8) 6.3 Reference 0.001
High 646 156 (24.2) 4.1 1.75(1.26–2.42) <0.001 48% 71%
Distal Colon 1990 247 (12.4) 8.1 2.96(2.18–4.03)
Low 711 48 (6.8) 14.8 Reference
Intermediate 633 73 (11.5) 8.7 1.80(1.23–2.63) 0.002
High 646 126 (19.5) 5.1 3.35(2.35–4.76) <0.001 51% 70%
Rectum 1990 93 (4.7) 21.4
Low 711 18 (2.5) 39.5 Reference
Intermediate 633 28 (4.4) 22.6 1.78(0.98–3.25) 0.060
High 646 47 (7.3) 13.7 3.02(1.74–5.26) <0.001 51% 68%
Framingham Risk Score (FRS) tertiles showed significant associations with detection-rates of any adenoma by
location (proximal colon, distal colon, and rectum). ORs (95% CI) for FRS high vs. intermediate (reference), for
presence of adenoma in prox. colon—1.70 (1.28–2.24) (p = 0.000). ORs (95% CI) for FRS high vs. intermediate
(reference), for presence of adenoma in dist. colon—1.86 (1.36–2.54) (p = 0.000). ORs (95% CI) for FRS high vs.
intermediate (reference), for presence of adenoma in the rectum—1.70 (1.05–2.74) (p = 0.032).
Table 6. Associations of the Heart Score (HS) Tertiles with colorectal lesion, by location.
HS-Tertiles N N (%) with AnyAdenoma
N to be
Screened OR (95% CI) p-Value Sensitivity Specificity
Proximal
Colon 1990 325 (16.3) 6.1
Low 711 62 (8.7) 11.5
Intermediate 633 111 (17.5) 5.7 Reference <0.001
High 646 152 (23.5) 4.3 2.23 (1.60–3.10 <0.001 47% 70%
Distal Colon 1990 247 (12.4) 8.1 3.22(2.34–4.43)
Low 711 47 (6.6) 15.1
Intermediate 633 85 (13.4) 7.4 Reference <0.001
High 646 115 (17.8) 5.6 2.19(1.51–3.18) <0.001 47% 70%
Rectum 1990 93 (4.7) 21.4 3.06(2.14–4.38)
Low 711 22 (3.1) 32.3
Intermediate 633 33 (5.2) 19.2 Reference 0.053
High 646 38 (5.9) 17 1.72(0.99–2.99) 0.014 41% 68%
The Heart Score (HS) of the European Society of Cardiology tertiles showed significant associations with detection
rates of any adenoma by location (proximal colon, distal colon, and rectum). ORs (95% CI) for HS high vs.
intermediate (reference), for presence of adenoma in prox. colon—1.45 (1.10–1.90) (p = 0.008). ORs (95% CI) for HS
high vs. intermediate (reference), for presence of adenoma in dist. colon—1.40 (1.03–1.89) (p = 0.032). ORs (95% CI)
for HS high vs. intermediate (reference), for presence of adenoma in rectum—1.14 (0.70–1.84) (p = 0.602).
Previously, the FRS was used to distinguish low, intermediate, and high cardiovascular risk, by
using <11%, 11–20%, and >20% as the cut-off values. Likewise, the cut-off values of HS were <1%,
1–5%, >5% or <3%, 3–6%, and >6%. Results for these strata are shown in Supplementary Tables S2–S5;
they led to largely comparable results.
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Table 7. Correlation matrix, the upper number indicating Spearman’s rho, the lower indicating the p-values.
IFG
[yes/no]
IGT
[yes/no]
HOMA
[index] FRS [%] HS [%] Polyps [n]
Tubular
Adenoma
[yes/no]]
Advanced
Neoplasia
[yes/no]
Adenoma in
Proximal
Colon [n]
Adenoma in
Distal
Colon [n]
Adenoma in
Rectum [n]
IFG [yes/no] —
—
IGT [yes/no] 0.123 —
<0.001 —
HOMA [index]
0.283 0.105 —
<0.001 <0.001 —
FRS [%]
0.176 0.15 0.25 —
<0.001 <0.001 <0.001 —
HS [%]
0.184 0.14 0.208 0.802 —
<0.001 <0.001 <0.001 <0.001 —
polyps [n] 0.031 0.054 0.111 0.238 0.237 —
0.16 0.013 <0.001 <0.001 <0.001 —
tubular adenoma
[yes/no]]
0.039 0.045 0.095 0.212 0.222 0.92 —
0.077 0.04 <0.001 <0.001 <0.001 <0.001 —
advanced neoplasia
[yes/no]
0.005 0.053 0.053 0.1 0.096 0.317 0.087 —
0.833 0.015 0.047 <0.001 <0.001 <0.001 <0.001 —
adenoma in proximal
colon [n]
0.02 0.043 0.07 0.179 0.191 0.728 0.707 0.223 —
0.36 0.047 0.008 <0.001 <0.001 <0.001 <0.001 <0.001 —
adenoma in distal
colon [n]
0.031 0.038 0.117 0.165 0.156 0.64 0.592 0.221 0.169 —
0.152 0.081 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 —
adenoma in rectum [n]
0.024 0.028 0.033 0.096 0.081 0.367 0.305 0.15 0.036 0.115 —
0.264 0.194 0.216 <0.001 <0.001 <0.001 <0.001 <0.001 0.096 <0.001 —
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3.3. Diabetes Mellitus and the Metabolic Syndrome
Subjects diagnosed with metabolic syndrome had a significantly higher cardiovascular risk
estimated both by the FRS tertiles (p < 0.001) and the HS tertiles (p < 0.001). Whereas, the prevalence of
adenomas in the proximal colon was significantly higher in subjects with type 2 diabetes (p = 0.006),
no statistically significant relationship between the adenomas and type 2 diabetes was observed
in the distal colon (p = 0.618) and the rectum (0.071). As both the FRS and the HS were initially
designed for non-diabetic subjects, we re-calculated our entire results for non-diabetic subjects only
(i.e., 1990 − 262 = 1728), with essentially the same results (data not shown). As in a real-world setting
of the screening colonoscopy, diabetic and non-diabetic subjects are screened alike, we refrained
from excluding all diabetic subjects, a priori from our analysis, in order to reach a higher statistical
power and a greater generalizability of our results. A correlation matrix including the IFG, IGT, and
HOMA-IR is depicted in Table 7. The FRS and HS performed better than HOMA, IFG, or IGT.
3.4. Comparison for Sex Differences
As male gender and age is a risk factor for both cardiovascular diseases and CRC, we performed
a sex-specific analysis of our data, as shown in Table 8. There was no difference in age between males
and females. Generally, males had an increased CVR, as compared to females, and accordingly a
significantly higher number of findings, during the screening colonoscopy. There were, however, no
site-specific differences of the detected lesions between the male and the female participants.
Table 8. Sex-specific differences with regard to cardiovascular risk and location of neoplasia.
Males Females p-Value
n 1051 1047 n.a.
Age (years; mean ± SD) 58.8 ± 9.4 59.5 ± 10.1 0.152
CAD (n [%]) 69 (6.6) 39 (3.7) 0.003
FRH (%; mean ± SD) 10.6 ± 6.1 4.0 ± 4.1 <0.001
HS (%; mean ± SD) 3.7 ± 3.9 2.5 ± 3.3 <0.001
Arterial hypertension (n [%]) 701 (66.7) 611 (58.4) <0.001
BMI (kg/m2; mean ± SD) 27.6 ± 4.1 26.8 ± 5.5 <0.001
Diabetes mellitus (n [%]) 161 (15.3) 136 (13.0) 0.126
Any adenoma 371 (35.3%) 218 (20.8%) <0.001
Any adenoma (total number of adenomas detected) (n [%]) 630 338 <0.001
Advanced neopasia (n [%]) 67 (6.4) 41 (3.9) 0.011
Adenoma in proximal colon (n [%]) 220 (20.9) 130 (12.4) <0.001
Adenoma in distal colon (n [%]) 166 (15.8) 100 (9.6) <0.001
Adenoma in rectum (n [%]) 71 (6.8) 30 (2.9) <0.001
Males had significantly more cardiovascular risk factors than females and, accordingly, more lesions were found in
males. However, no site-specific differences could be found.
4. Discussion
We report that cardiovascular risk, regardless of using the FRS or the HS, was associated with an
increased risk of adenomas in the proximal and the distal colon, in asymptomatic subjects undergoing
screening colonoscopy. In the rectum, the difference in distribution was more pronounced in the
FRS. Furthermore, in patients with type 2 diabetes, we found significantly more adenomas in the
proximal colon.
4.1. The Rationale for Site-Specific Risk Factors in CRC
As previously suggested, several biological differences might be present among malignancies
originating from the proximal and the distal colon and the rectum, which lead to the suggestion
of splitting these entities into three different tumors [4]. These biological differences might explain
why several risk factors might affect the CRC risk, differently, by location. First, the embryological
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differences among the different locations might affect the susceptibility to carcinogens. The area
including the cecum, the ascending colon, and the proximal two-thirds of the transverse colon,
originates from the midgut, while the rest originates from the hindgut [2,35]. Second, subsite differences
may be due to differences in tumor methylation status, BRAF (gene encoding for b-raf i.e. rapidly
accelerated fibrosarcoma) and KRAS (proto-oncogene that acts as an on/off switch in cell signaling,
named after Kirsten RAt Sarcoma virus) mutation status, as well as DNA microsattelite instability.
Proximal tumors appear to be related to the CpG island methylator phenotype (CIMP)-high and the
BRAF-mutated tumors, while the distal tumors were found to be mostly related to the no-CIMP and
microsatellite stable tumors. Additionally, tumors in the cecum were frequently associated to a high
frequency of the KRAS mutations [36].
Several authors have studied the subsite-specific risk factors, with conflicting results [8,10–14].
A systematic review on the subject, by Benedix et al., concluded that proximal colon cancer was
found more frequently in women, patients of older age, and in regions with lower incidence rates
for colorectal carcinoma. Furthermore, they described a better response rate to 5-fluoruracil-based
chemotherapy in patients with right-sided colon carcinoma [37]. Such site-specific differences would
have several clinical implications. On one hand, patients at risk for proximal colon cancer might benefit
especially from a complete colonoscopy. On the other hand, future genetic, clinical, and treatment
studies need to assess not only the effects of the medication in general, but also compare the effects
in relation to the location of the tumor (i.e., proximal vs. distal colon). Should the hypothesis of two
different tumor entities be confirmed, a location-specific therapy, and, in the case of subsite-specific
risk factors, a location-specific screening and preventive strategy, according to the risk factors, may
be required.
4.2. Site-Specific Risk Factors for CRC
Therefore, the main goal of this study was to investigate the site-specific differences in patients
with different FRS and HS risk scores. FRS and HS showed incremental risk for colorectal adenoma,
across tertiles, in both proximal and distal colon. However, in the rectum, the difference in distribution
was more pronounced in the FRS. Along with a different prediction (FRS: ten-year risk of heart
attack, HS: ten-year risk of cardiovascular death), the FRS includes the HDL-cholesterol, which the HS
does not, whereas, the HS uses different models for different countries of origin. The more accurate
association with FRS might underline the importance of the HDL-cholesterol, a risk factor that can
be altered mainly by lifestyle interventions (healthy diet, regular exercise), in the rectal neoplasm.
Howard et al. have previously shown that regular physical activity is more protective in the rectal
than in the colonic neoplasm [12]. Interestingly, our data show the expected increased CVR in males
and, consequently, a higher detection-rate of premalignant lesions, during the screening colonoscopy.
However, we did not find sex differences with regard to the site-specific aspects, which other studies
have found [37].
In line with our findings, in a community-based cohort of adults aged >50 years, Laird-Fick et al.
showed that the polyps were most often found in the right sided colon, whereas the prevalence of
polyps in the rectum was lowest with only 0.7% of lesions found in the rectum [38].
4.3. Diabetes Mellitus Type 2 and Metabolic Syndrome
Previously, the metabolic syndrome and type 2 diabetes have been linked to CRC [39]. In a
meta-analysis by Larsson et al., it was concluded that diabetes mellitus was associated with an
increased CRC risk in both men and women [40]. This association was also found in more recent
meta-analyses [36,41]. Already in 1995, a hypothesis involving hyperinsulinemia was proposed to
explain the association between diabetes mellitus and CRC risk [42]. It was presumed that the insulin
resistance in patients with diabetes mellitus leads to a chronic hyperinsulinemic state and elevation
of insulin-like growth factor-1 levels; this plays a crucial role in the cell proliferation and finally in
the occurrence of CRC [42]. Furthermore, Kiunga et al. conducted an in vivo study in which they
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showed that insulin receptors contribute to the cell transformation [43]. This led to the hypothesis
that elevated insulin receptor protein expression in colonic tumors might be a possible mechanism
for tumorigenesis.
Regarding subsite-specific differences in patients with type 2 diabetes, several studies have
stated conflicting results [10,12,44]. When studying site-specific differences in patients with type 2
diabetes, we found that they had significantly more adenomas in the proximal than in the distal colon.
Our analysis revealed interesting results, in that, although the proportion of subjects with metabolic
syndrome and type 2 diabetes was significantly higher in the highest tertiles of both the FRS and the
HS, the metabolic syndrome and type 2 diabetes itself were not, or were only marginally associated
with colorectal adenomas, with one exception—subjects with type 2 diabetes had significantly more
adenomas in the proximal colon. This further highlights the need for a better understanding of the
complex relationship between diabetes, the metabolic syndrome, and cancer. As FRS and HS perform
better in our correlation matrix than the IFG, IGT, and the HOMA-IR, indicating an insulin resistance,
this suggests the incremental importance of pre-diabetic states to diabetes, on the development of
colorectal lesions.
4.4. Number Needed to Screen: Selecting High-Risk Patients for CRC to Increase the Detection-Rate
Several prior investigations studied various risk scores to select the high-risk subjects in a
screening cohort and consequently lower the number needed to screen [45–51]. Variables that
were considered included, age, sex, family history of CRC, BMI, smoking, dietary habits, prior
colonoscopy and the results, thereof, included the use of non-steroidal anti-inflammatory drugs and
waist circumference. The degree of lowering of the numbers needed to screen we report, herewith, is
comparable to these previously published studies [45–51].
Since up to 10% of CRC occur in subjects younger than 50 years and also myocardial infarction
is seen in 4–10% in subjects ≤ 40–45 years, we think there is no good reason to a priori exclude the
younger subjects from the analysis, as others have done [52,53].
Several reports, with conflicting results related to the preventive nature of statins and metformin,
have been published previously [54,55]. We, therefore, did not control our analysis for the use of
statins or metformin. With respect to Aspirin, the published evidence strongly suggests a protective
effect against CRC [56,57]. As most Aspirin users have an increased CVR, in our cohort, Aspirin was
not protective but rather associated with a higher risk, presumably reflecting the higher prevalence of
common risk factors of subjects taking aspirin.
In light of the emerging importance of disease prevention and health screening programs, the
previously published studies, as well as our data, underline the need for screening initiatives including
screening colonoscopy. In health screening initiatives, in general, the NNS is crucial. With regard
to screening colonoscopy in a large Austrian screening cohort, Ferlitsch et al. reported an NNS of
5.1 (95% CI, 5.0–5.2), 15.9 (95% CI, 15.4–16.5), and 90.9 (95% CI, 83.3–100.0), for colorectal adenoma,
advanced adenoma, and CRC, respectively [58]. In representative studies on screening colonoscopy
in different ethnicities, and the risk estimation in colonoscopy, the main outcome that was defined
as advanced adenoma/neoplasia, varied between 3.0% and 11.2% [42–48]. Although the number
of advanced neoplasia we report is at the lower end of this range (3.8%), our NNS was below the
previously reported value by Ferlitsch et al., as only four subjects had to be screened to detect an
adenoma, and only twenty seven to detect an advanced neoplasia (i.e., advanced adenoma and CRC).
Ferlitsch et al. reported an advanced adenoma and CRC, separately; unfortunately, we could not
provide meaningful calculations, due to the lower number of screened subjects in our study (44,350
vs. 2089) [58]. However, the numbers needed to screen, which we have reported, get even lower, as
the CVR rises (in high CVR, for adenoma, it is three for advanced neoplasia, depending on the risk
score—15 or 17), indicating a solid basis for a recommendation of screening colonoscopy, especially in
subjects with high CVR. Of note, the NNS were lower in the proximal colon (6.1) than in the distal
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colon (8.1), and rectum (21.4), and the increment of the NNS, as the CVR changed, persisted in all three
colorectal regions.
4.5. Coronary Artery Disease, Cardiovascular Risk, and Colorectal Cancer: Potential Mechanisms, Integration
into a Holistic Diagnostic Approach, and Future (Practical) Considerations
The association between CAD, diabetes, and colorectal neoplasia that we have reported in this
paper, raises questions about the possible common pathogenetic factors. Several possible explanations
have previously been suggested, among them are the shared risk factors, such as obesity, sedentary
lifestyle, diabetes mellitus, hypertension, and cigarette smoking [15–21]. On the molecular level,
several shared risk factors may underlie the common pathways, with inflammation appearing to be a
major contributor. However, insulin resistance, reactive oxygen species and oxidative stress, hormones
(e.g., leptin), cytokines, growth factors, and other metabolic reactions have also been linked to CAD
and cancer. [21]. Only recently, HMGA-1 (High-mobility group protein A1) a structural chromatin
protein was shown to be involved in cancer and its invasiveness in breast cancer [59]. In addition, a
specific variant of HMGA-1 has been found to increase the risk for diabetes, coronary artery disease,
and acute myocardial infarction [60]. This fascinating interaction of the same protein being involved
in cancer invasiveness and risk for diabetes, CAD, and acute coronary syndrome, offers a potential
molecular explanation of our findings that, to our knowledge, has not been studied yet.
Also, the prognostic value of noninvasive biomarkers and investigations, such as microRNAs,
microbiota-related aspects, or noninvasive imaging, are of interest, with regard to our data in further
risk stratifying subjects, for screening colonoscopy. MicroRNAs have shown promising preliminary
results for both diagnostic and prognostic assessment of cardiovascular disease in patients with
diabetes and, if integrated in a holistic risk stratification tool, might help to select the appropriate
subjects in the right time-frame, to avoid unnecessary screening procedures [61]. We have previously
shown the value of using a specific pattern of microbiota to test stools of screening candidates [62]. It is
now widely accepted that microbiota is also involved in atherosclerosis, however, the exact overlap
of microbiota between cardiovascular and gastrointestinal pathologies remains to be elucidated.
Noninvasive imaging biomarkers might also be helpful in this context. In particular, a novel modality
to assess the flow-mediated dilation that takes into account the time needed for dilation of the brachial
artery, was recently tested, and the results showed promise for the successful exclusion of the presence
of critical coronary stenoses (>=70%), before performing invasive coronary angiography [63]. Again,
data of tests, such as flow-mediated dilation could help to better recommend the time and population
for screening colonoscopy, in terms of a personalized screening approach.
We report an association between colorectal neoplasia and CAD, meaning that no conclusions
regarding causality can be drawn from our data. It follows naturally that the association works in both
ways. Cardiologists or diabetologists that take care for patients with CAD, increased CVR, or diabetes
should have the possibility of CRC in mind, and gastroenterologists that diagnose CRC or colorectal
neoplasia, should think about the cardiovascular health of their patients. We, therefore, propose five
distinct clinical scenarios, based on our results and pre-existing clinical evidence on how an updated,
more individualized screening approach might look like, as outlined in Figure 3.
Epidemiological data of the potential dimension of the clinical problem of patients with CRC
and high cardiovascular risk is sparse. We report, in a real-world screening population for CRC,
5.2% of subjects with CAD and, depending on the definition, approximately 15% of subjects with
high cardiovascular risk. Taken together, approximately 20% of our screened subjects, that is about
four hundred and twenty out of two thousand and ninety-eight subjects, may be defined as the
scope of the clinical problem, with potential overlap between colorectal neoplasia and cardiovascular
disease. With an estimated number of 14–15 million people with cardiovascular disease (excluding
hypertension) in the United States alone, that also have a history of cancer, this number might even
be higher [67,68]. If our findings apply to every fifth patient in a real-world screening population, an
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average cardiologist, gastroenterologist, or a diabetologist, will face the clinical scenario we report on
(i.e., a subject with shared risk factors for CRC and CAD), virtually every day.
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4.6. Strengths and Limitations
Although several studie on th topic of shared isk factors of CAD/CVR and CRC have been
published previously, our inv stigation was unique for several reasons. First, no study so far assessed
a Caucasian population with respect to cardiovascular risk and its relationship to CRC. CVD and
CRC showed considerable ethnic differences, and studies that were mostly conducted in Asia do
not necessarily reflect the Caucasian situation. Furthermore, exactly for the same reason, the HS
was developed by the ESC (European Society of Cardiology), as existing risk-prediction tools, like
the FRS only insufficiently predicted cardiovascular risk in Europe, and the HS of the ESC has two
versions for low-risk and high-risk countries in Europe, to account for the regional differences [69–71].
No previous study used HS to correlate findings in a screening colonoscopy. In addition, we did not
exclude subjects with known CAD, and showed that in known CAD, the risk for colorectal neoplasia
is even higher than in the non-CAD population. The increase in OR per percentage point of both
FRS and HS we reported, was in line with this finding. With respect to the assessment of diabetes
and metabolic syndrome, we reported a detailed investigation of the metabolic profile, including oral
glucose tolerance test in every patient.
In our study, CAD was only established via questionnaire or medical history.
Coronary angiography was available in 51% of subjects that reported a known CAD and the
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angiographically-verified CAD patients did not differ significantly in any aspect, as compared to
subjects that reported a known CAD, except for aspirin use. This finding and the fact that self-reported
CAD is significantly associated with CVR and also risk for CRC, make a relevant wrongful reporting
of known CAD in subjects with unknown coronary status, unlikely. However, some subjects might
not be aware of the fact that they actually have CAD. In case our records did not reveal a known
CAD, we might naturally have missed subjects with known CAD. We think such a misrepresentation
would only marginally change our results. In addition, it would be highly unethical to screen such a
large cohort using coronary angiography, the gold standard for the diagnosis of CAD. Additionally, a
Hong Kong study used subjects that needed a coronary angiography due to suspected CAD, which
also imposed a bias to the study population. Other screening methods for CAD in asymptomatic
subjects were shown to be problematic, due to the low sensitivity and specificity, so we think that
no substantial improvement of a definite diagnosis of CAD is feasible in such a large screening
cohort [15,72]. Although we included a large number of subjects, the number of advanced colorectal
neoplasia per site was too low to draw reliable conclusions. Our results should be regarded as
rather hypothesis-generating, and future studies with even larger cohorts are needed to answer such
site-specific questions.
5. Conclusions
In conclusion, we report a risk factor-dependent association between the cardiovascular risk
factors and the incidence of neoplasia, in both the proximal and the distal colon, presumably due to
the shared risk factors. The prevalence of adenomas in the rectum was much lower than in the colon,
and significant incremental risk could be shown for the FRS but not the HS tertiles. We further report
that subjects with type 2 diabetes had significantly more adenomas in the proximal than in the distal
colon. This might highlight the importance of a complete colonoscopy, especially, in patients with
type 2 diabetes. Our data suggest screening colonoscopy to be indicated particularly in subjects with
known coronary artery disease or high cardiovascular risk, in order to detect potentially treatable
colorectal neoplasia.
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